Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes

Cardiovascular Research

Volumn 31, Issue 6, 1996, Pages 963-974

  Cheng, Jianhua ^a   Kamiya, Kaichiro ^a   Kodama, Itsuo ^a   Toyama, Junji ^a  

^a NAGOYA UNIVERSITY   (Japan)

Author keywords

Antiarrhythmic drugs; Delayed rectifier; E 4031; Membrane potential; MS 551; Potassium channel; Rabbit, ventricular myocytes; Use dependence

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; NIFEKALANT; POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTROPHYSIOLOGY; HEART ARRHYTHMIA; HEART MUSCLE CELL; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; FEMALE; MALE; MYOCARDIUM; NA(+)-K(+)-EXCHANGING ATPASE; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PYRIDINES; PYRIMIDINONES; RABBITS;

EID: 0030014309     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/0008-6363(96)00049-1     Document Type: Article

References (34)

1. Woosley RL. Antiarrhythmic drugs. Annu Rev Pharmacol Toxicol 1991;31:427-455.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412.
3. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
4. Hafner D, Berger F, Borchard U, Kullmann A, Scherlitz A. Electrophysiological characterization of the class III activity of sotalol and its enantiomers: new interpretation of use-dependent effects. Drug Res 1988;38:231-236.
5. K blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990; 16:401-410.
6. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW, Higgins AJ. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-324.
7. Gwilt M, Dalrymple HW, Burges RA, Blackburn KJ, Dickinson RP, Cross PE, Higgins AJ. Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol 1991;17:376-385.
8. Carlsson L, Abrahamsson C, Almgren O, Lundberg C, Duker G. Prolonged action potential duration and positive inotropy induced by the novel class III antiarrhythmic agent H234/09 (almokalant) in isolated human ventricular muscle. J Cardiovasc Pharmacol 1991; 18:882-887.
9. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-817.
10. + current by almokalant in rabbit ventricular myocytes. Circ Res 1993;73:857-868.
11. + current by quinidine in rabbit sinoatrial and atrioventricular nodes. J Pharmacol Exp Ther 1989;251:756-763.
12. Duan D, Fermini B, Nattel S. Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 1993;264:1113-1123.
13. c antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res 1992;26:1121-1130.
14. Hashimoto K, Ishii M, Kamiya J. Cellular electrophysiological effects of MS-551, a new class III antiarrhythmic agent, in various cardiac tissue: comparison of d-sotalol (Abstract). Eur J Pharmacol 1990;183:1164.
15. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993;109: 157-163.
16. Wettwer E, Scholtysik G, Schaad A, Himmel H, Ravens U. Effects of new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol 1991;17:480-487.
17. Yazawa K, Kaibara M, Ohara M, Kameyama M. An improved method for isolating cardiac myocytes useful for patch-clamp studies. Jpn J Physiol 1990;40:157-163.
18. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflügers Arch 1981;391:85-100.
19. + current in guinea pig heart cells. Am J Physiol 1987;253:H1321-1324.
20. Shimoni Y, Clark RB, Giles WR. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J Physiol 1992;448:709-727.
21. Giles W, Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J Physiol 1988;405:123-145.
22. Hiraoka M, Kawano S. Calcium-sensitive and insensitive transient outward current in rabbit ventricular myocytes. J Physiol 1989;410: 187-212.
23. Fedida, D, Diles, WR. Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J Physiol 1991;442:191-209.
24. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating arrhythmias. Circulation 1990; 82:2235-2242.
25. Noble D, Tsien RW. Outward membrane currents activated in the plateau range of potentials in cardiac Purkinje fibers. J Physiol 1969;82:289-293.
26. Surawicz B. Electrophysiological substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol 1989;14:171-184.
27. Surawicz B. Role of potassium channels in length dependent regulation of action potential duration in mammalian cardiac Purkinje and ventricular muscle fibres. Cardiovasc Res 1992;26:1021-9.
28. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
29. + current similar to Kv 1.5 cloned channel currents. Circ Res 1993;73:1061-1076.
30. Wang Z, Fermini B, Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc Res 1994;28:1540-1546.
31. Nánási PP, Varró A, Lathrop DA. Ionic currents in ventricular myocytes isolated from the heart of a patient with idiopathic cardiomyopathy. Cardioscience 1992;3:85-89.
32. + currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res 1993;73:379-385.
33. Ohler A, Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 1994;270:460-465.
34. Spinelli W, Moubarak IF, Parsonss RW, Colatsky TJ. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of block and lack of reverse use dependence in cat ventricular myocytes. Cardiovasc Res 1993;27:1580-1591.